This phase I trial studies how well indocyanine green works in imaging patients with solid tumors or lymphoma who are undergoing surgery. Indocyanine green is a solution given before surgery that may make a tumor or lump easier for doctors to see so that it can be taken out completely.
Additional locations may be listed on ClinicalTrials.gov for NCT04084067.
Locations matching your search criteria
United States
Tennessee
Memphis
Saint Jude Children's Research HospitalStatus: Active
Contact: Lindsay Jones Talbot
Phone: 901-595-3300
PRIMARY OBJECTIVE:
I. To assess the feasibility of indocyanine green (ICG)-mediated near-infrared (NIR) imagery to identify neoplastic disease during the conduct of surgery to resect neoplastic lesions in children and adolescents.
EXPLORATORY OBJECTIVES:
I. To compare the ICG uptake by primary versus (vs) metastatic site and pre-treated (chemotherapy, radiation, or both) vs non-pre-treated.
II. Assess the sensitivity and specificity of NIR imagery to find additional lesions not identified by standard of care intraoperative inspection and tactile feedback.
III. Assess the sensitivity and specificity of NIR imagery to find additional lesions not identified on preoperative diagnostic imaging.
IV. Assess the sensitivity and specificity of NIR imagery for identifying residual disease at the conclusion of a tumor resection.
OUTLINE:
Patients receive indocyanine green intravenously (IV) over 15 minutes 1-3 days prior to undergoing tumor imaging and surgical resection on study.
After completion of study, patients are followed up for 24 hours.
Lead OrganizationSaint Jude Children's Research Hospital
Principal InvestigatorLindsay Jones Talbot
